Your browser doesn't support javascript.
loading
A single dose SARS-CoV-2 simulating particle vaccine induces potent neutralizing activities
Yujia Cai; Di Yin; Sikai Ling; Xiaolong Tian; Yang Li; Zhijue Xu; Hewei Jiang; Xue Zhang; Xiaoyuan Wang; Yi Shi; Yan Zhang; Lindai Da; Sheng-ce Tao; Quanjun Wang; Jianjiang Xu; Tianlei Ying; Jiaxu Hong.
Affiliation
  • Yujia Cai; Shanghai Jiao Tong University
  • Di Yin; Shanghai Jiao Tong University
  • Sikai Ling; Shanghai Jiao Tong University
  • Xiaolong Tian; Fudan University
  • Yang Li; Shanghai Jiao Tong University
  • Zhijue Xu; Shanghai Jiao Tong University
  • Hewei Jiang; Shanghai Jiao Tong University
  • Xue Zhang; Shanghai Jiao Tong University
  • Xiaoyuan Wang; BD Gene Therapeutics
  • Yi Shi; Shanghai Jiao Tong University
  • Yan Zhang; Shanghai Jiao Tong University
  • Lindai Da; Shanghai Jiao Tong University
  • Sheng-ce Tao; Shanghai Jiao Tong University
  • Quanjun Wang; Academy of Military Sciences
  • Jianjiang Xu; Fudan University
  • Tianlei Ying; Fudan University
  • Jiaxu Hong; Fudan University
Preprint in En | PREPRINT-BIORXIV | ID: ppbiorxiv-093054
ABSTRACT
Coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) for which a vaccine is urgently needed to control its spreading. To facilitate the representation of a native-like immunogen without being infectious, here, we reported a SARS-CoV-2 vaccine candidate (designated ShaCoVacc) by incorporating spike-encoding mRNA inside and decorating spike protein on the surface of the virus simulating particles (VSPs) derived from lentiviral particles. We characterized the mRNA copy number, glycosylation status, transduction efficiency, and innate immune property of the new vaccine platform. Importantly, we showed the ShaCoVacc induced strong spike-specific humoral immune responses and potent neutralizing activities by a single injection. Additionally, we disclosed the epitopes of spike-specific antibodies using peptide microarray and revealed epitopes susceptible to specific neutralizing antibodies. These results support further development of ShaCoVacc as a candidate vaccine for COVID-19 and VSP may serve as a new vaccine platform for emerging infectious diseases.
License
cc_by_nc_nd
Full text: 1 Collection: 09-preprints Database: PREPRINT-BIORXIV Language: En Year: 2020 Document type: Preprint
Full text: 1 Collection: 09-preprints Database: PREPRINT-BIORXIV Language: En Year: 2020 Document type: Preprint